NOT KNOWN FACTUAL STATEMENTS ABOUT PALBOCICLIB

Indicated as monotherapy for adults with HR-favourable, HER2-detrimental Innovative or metastatic breast cancer with sickness progression following endocrine therapy and prior chemotherapy in metastatic location 200 mg PO BIDMedications that have amount limitations associated with Just about every prescription. This restriction generally limits the